The Milner Therapeutics Consortium
The Consortium is an academic/industry partnership hosted by the Institute and part of its outreach programme. The Consortium has been active since June 2015 and is based on a research agreement signed by three academic centres, the University of Cambridge, the Sanger Institute and the Barbaham Institute and four pharmaceutical companies, Astex, AstraZeneca, GlaxoSmithKline and Shionogi. The agreement is designed to facilitate the speedy exchange of reagents and information and underpin research collaborations. The Consortium will provide researchers with the potential to access novel therapeutic agents (including small molecules and antibodies) across the entire portfolio of drugs being developed by each of the companies, in order to investigate their mechanism, efficacy and potential.
Each industry partner within the Therapeutics Consortium has set aside funds for collaborative research projects between the Consortium members, which will be open to any therapeutic area and are expected to lead to joint publications. For information on current projects click here. For information on company areas of interest click here.
The terms of the Consortium allow for fast and easy access to agents and information. The academic/industry interactions and match-making are facilitated by the Executive Manager.
If you are interested in joining the Consortium please contact firstname.lastname@example.org.
The Milner Therapeutics Consortium Innovation Board
The Innovation Board brings together the industrial and academic partners of the Consortium to determine the overarching challenges facing the pharmaceutical industry and predict future needs. It enables companies to collaborate on common research projects related to targets, technologies and therapeutic areas. The Consortium companies are in a position to fund collectively major projects of common interest. Its remit is to consider the future direction of therapeutic research and suggest innovative projects for collective company funding. Research projects selected by the Innovation Board are executed by a 'task force' of academic and company groups with appropriate expertise. Please contact email@example.com for more information.
Innovation Board Membership
Dr Susan Galbraith, Vice President, Head of Oncology iMed, Innovative Medicines
Dr Sabina Cosulich, Director, Oncology Bioscience, Innovative Medicines
Dr Neil Thompson, Senior Vice President, Biology
Dr David Rees, Senior Vice President, Chemistry
Dr Rab Prinjha, Vice President, Head of Epigenetics DPU
Dr Ron Newbold, Vice President, External R&D Innovation
Dr Takeshi Shiota, Senior Vice President, Pharmaceutical Research Division
Dr Kai Stoeber, Vice President, Global Innovation
Dr Mathew Garnett, Group Leader, Translational Cancer Genomics
Professor Michael Wakelam, Director
Dr Simon Cook, Group Leader, Signalling Programme
|University of Cambridge||Professor Tony Kouzarides, Deputy Director, Gurdon Institute|